APEC1621N NCI-COG PEdiatric Match (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients with Tumors Harboring RET Gene Alterations

NCT04320888

NCI-COG PEdiatric Match (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients with Tumors Harboring RET Gene Alterations

Associated Conditions

Multiple Tumor Types

Principal Investigator

Sponsor

Children's Oncology Group

This is a Phase 2 study of a drug called LOXO-292. In a Phase 2 study, the goal is to find out what effects, good and/or bad, a drug has on your tumor or type of cancer. LOXO-292 is experimental because it has not been proven to work in a situation like yours.